BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dawed AY, Mari A, Brown A, McDonald TJ, Li L, Wang S, Hong MG, Sharma S, Robertson NR, Mahajan A, Wang X, Walker M, Gough S, Hart LM', Zhou K, Forgie I, Ruetten H, Pavo I, Bhatnagar P, Jones AG, Pearson ER; DIRECT consortium. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabetes Endocrinol 2023;11:33-41. [PMID: 36528349 DOI: 10.1016/S2213-8587(22)00340-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Drucker DJ, Holst JJ. The expanding incretin universe: from basic biology to clinical translation. Diabetologia 2023. [PMID: 36976349 DOI: 10.1007/s00125-023-05906-7] [Reference Citation Analysis]
2 Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 2023. [PMID: 36977782 DOI: 10.1038/s41569-023-00849-3] [Reference Citation Analysis]
3 Saiti A, Giannopoulos-dimitriou A, Kazakos I, Galatou E, Vizirianakis IS. Systems Pharmacology and Network Analysis to Advance Pharmacogenomics and Precision Medicine Decisions in Type-2 Diabetes Therapy. Future Pharmacology 2023;3:329-363. [DOI: 10.3390/futurepharmacol3010021] [Reference Citation Analysis]
4 Sladek R. Predicting the response to GLP-1 receptor agonists: an unexpected role for β-arrestin-1. Lancet Diabetes Endocrinol 2023;11:3-4. [PMID: 36528348 DOI: 10.1016/S2213-8587(22)00357-6] [Reference Citation Analysis]